RELIVE
International registry for paediatric patients with relapsed or refractory hepatoblastoma or hepatocellular carcinoma
Liver tumours
Long-term outcome for patients with refractory or relapsed HB, HCC, and HCN-NOS is unsatisfactory. The international consortium currently conducting the PHITT trial plans to incorporate treatment guidelines and data acquisition for relapsed and refractory patients in a prospective fashion as part of a second-generation protocol. To guide writing of this future proposal, the RELIVE consortium is proposing a retrospective collection of data regarding recently utilized treatment regimens as well as short- and long-term patient outcomes. Anecdotal information is insufficient; therefore, we propose to retrospectively collect cases in a central registry allowing for a systematic overview and statistical assessment of the various approaches used.
- To achieve an overview of the past approaches and recent developments in the treatment of refractory or relapsed HB, HCC or HCN NOS in children, and
- To investigate the short- and long-term outcomes inpatients treated with these regimens in order to identify the most promising treatment approaches for this patient cohort.
Disease Stage: n/a
Patient Age Range: < 18 years at first diagnosis of liver tumour
Trial sponsors
- National – ANZCHOG
- International – Geneva University Hospital
